Pages
-
-
Multi-ancestry genome-wide association analyses identify novel genetic mechanisms in rheumatoid arthritis
-
-
Tofacitinib in combination with methotrexate in patients with rheumatoid arthritis: patient-reported outcomes from the 24-month Phase 3 ORAL Scan study
-
-
Tofacitinib in Combination With Methotrexate in Patients With Rheumatoid Arthritis: Clinical Efficacy, Radiographic, and Safety Outcomes From a Twenty-Four-Month, Phase III Study
-
-
14-3-3 eta Autoantibodies: Diagnostic Use in Early Rheumatoid Arthritis
-
-
Sociodemographic and Health Status Characteristics Explain Five Clinical Outcome and Radiographic Trajectories in Early Rheumatoid Arthritis: Data from the CATCH Cohort
-
-
Long-term safety and efficacy of certolizumab pegol in combination with methotrexate in the treatment of rheumatoid arthritis: 5-year results from the RAPID 1 trial and open-label extension
-
-
Citrullinated 14-3-3 eta Antibodies Are Specific for Early and Established RA and Are Complementary to ACPA
-
-
Long-Term Safety and Efficacy of Certolizumab Pegol in Combination with Methotrexate in the Treatment of Rheumatoid Arthritis: 5-Year Results from a 52-Week Randomized Controlled Trial and Open-Label Extension Study
-
-
Genetics of rheumatoid arthritis contributes to biology and drug discovery
-
-
Changes In Patient-Reported Joint Counts and Composite Indices Can Identify Flare Of Disease Activity In Recent Onset Rheumatoid Arthritis
-
-
Long-Term Safety and Efficacy Of Certolizumab Pegol In Combination With Methotrexate In The Treatment Of Rheumatoid Arthritis: 5-Year Results From a 52-Week Randomized Controlled Trial and Open-Label Extension Study
-
-
Reliability and Validity Of Patient-Reported Joint Counts and Determinants Of Disagreement With The Physician In Recent Onset Rheumatoid Arthritis
-
-
Oskira-3: A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Parallel-Group Study Of 2 Dosing Regimens Of Fostamatinib In Rheumatoid Arthritis Patients With An Inadequate Response To a Tumor Necrosis Factor-alpha Antagonist
-
-
Longterm Use of Adalimumab as Monotherapy Following Attainment of Low Disease Activity with Adalimumab plus Methotrexate
-
-
Achieving Comprehensive Disease Control in Long-Standing or Early Rheumatoid Arthritis Patients Treated with Adalimumab Plus Methotrexate versus Methotrexate Alone
-
-
Analysis of Integrated Radiographic Data for Two Longterm, Open-Label Extension Studies of Adalimumab
-
-
Effective Disease Control Following Up to 10 Years of Treatment with Adalimumab in Patients with Long-Standing Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Final 10-Year Results of the DE019 Trial
-
-
Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: Twelve-month data from a twenty-fourmonth phase III randomized radiographic study
-
-
Validation of a novel multibiomarker test to assess rheumatoid arthritis disease activity
-
-
Tofacitinib, an Oral Janus Kinase Inhibitor, in Combination with Methotrexate Reduced the Progression of Structural Damage in Patients with Rheumatoid Arthritis: Year 2 Efficacy and Safety Results From a 24-Month Phase 3 Study
-
-
INITIAL COMBINATION THERAPY WITH ADALIMUMAB PLUS METHOTREXATE LEADS TO BETTER LONG-TERM OUTCOMES THAN WITH EITHER MONOTHERAPY IN PATIENTS WITH EARLY RHEUMATOID ARTHRITIS: 8-YEAR RESULTS OF AN OPEN-LABEL EXTENSION OF A PHASE 3 TRIAL
-
-
Initial Combination Therapy with Adalimumab Plus Methotrexate Leads to Better Long-Term Outcomes in Patients with Advanced Rheumatoid Arthritis: Analysis of the Final 10-Year Results of An Open-Label Extension of a Phase 3 Trial
-
-
Initial Combination Therapy with Adalimumab Plus Methotrexate Leads to Better Long-Term Outcomes Than with Either Monotherapy in Patients with Early Rheumatoid Arthritis: 8-Year Results of An Open-Label Extension of a Phase 3 Trial
-
-
Changes in patient characteristics in anti-tumour necrosis factor clinical trials for rheumatoid arthritis: results of an analysis of the literature over the past 16 years
Pages
